

# WHO Drug Information

---

## Contents

### General Policy Topics

Microbes on the move 155

### Reports on Individual Drugs

Mini-dose warfarin: limitations in prevention of venous thrombosis 158

Low-dose acetylsalicylic acid in hypertensive pregnancy disorders 159

ACE inhibitors: a third pillar in the management of heart failure 161

Postmenopausal estrogen therapy: checks and balances 162

Intravenous immune globulin: a case study in cost-effectiveness 163

Penicillin, allergy and rheumatic heart disease 164

Poliomyelitis: setbacks in the timetable for eradication? 165

Thiomersal: time for a reassessment? 166

### General Information

What patients need to know 168

Acute poisonings: referral patterns in Zimbabwe 168

A new global children's vaccine initiative 169

New approaches to carcinogenicity testing 170

Pre-emptive therapy for immunocompromised patients 171

Hypertension in the elderly: the case for active intervention 172

Asthma: newly detected allergens have implications for treatment 173

### Regulatory Matters

Parenteral gangliosides and Guillain-Barré syndrome 175

Glafenine reassessed and further restricted 175

Loperamide: dangers in young children 176

Moracizine: for life-threatening post-infarction dysrhythmias only 176

Tacrine: approval refused for Alzheimer's disease 176

Terodiline and ventricular tachychardia 176

Bovine spongiform encephalopathy 176

### Advisory Notices

Cefalosporins and haemolysis 178

Dexfenfluramine and pulmonary hypertension 178

Identification codes for tablets and capsules 178

Flunarizine and extrapyramidal signs 178

Iron dextran and allergic reactions 179

Mercury in dental amalgam 179

Vitamin K and anaphylaxis 179

Quinine and thrombocytopenia 179

Quinolones and allergic reactions 179

Tienilic acid and hepatitis 180

### Essential Drugs

WHO Model List (latest revision) 181

### Proposed International

Nonproprietary Names: List 66 193